Published in Horm Cancer on April 01, 2012
Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res (2013) 1.02
PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Res (2013) 0.92
Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells. J Biol Chem (2013) 0.88
Pathways driving the endocytosis of mutant and wild-type EGFR in cancer. Oncoscience (2014) 0.87
Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer. Eur J Clin Invest (2013) 0.86
Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis. Oncogene (2015) 0.84
Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis. J Transl Med (2013) 0.81
Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage. Mol Cancer Ther (2012) 0.80
Sam68 is Overexpressed in Epithelial Ovarian Cancer and Promotes Tumor Cell Proliferation. Med Sci Monit (2016) 0.79
Role of Sam68 in post-transcriptional gene regulation. Int J Mol Sci (2013) 0.78
Sam68 is a novel marker for aggressive neuroblastoma. Onco Targets Ther (2013) 0.77
Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition. Biochemistry (2015) 0.77
The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer. Chin J Cancer (2016) 0.76
Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines. Cancer Gene Ther (2015) 0.75
Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells. PLoS One (2016) 0.75
The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR. Biochem Pharmacol (2016) 0.75
A summary of relationships between alternative splicing and breast cancer. Oncotarget (2017) 0.75
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Mammalian MAP kinase signalling cascades. Nature (2001) 18.89
Conserved structures and diversity of functions of RNA-binding proteins. Science (1994) 14.75
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Liver regeneration. Science (1997) 12.80
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68
Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol (2004) 6.36
Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (1987) 6.26
Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature (1995) 6.13
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol (1992) 5.04
Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell (1991) 4.98
Mechanism of met oncogene activation. Cell (1986) 4.20
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 4.10
Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A (1987) 3.99
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun (1984) 3.70
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene (1991) 3.41
An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature (1994) 3.30
Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A (1991) 3.27
Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature (2002) 3.17
CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev (2002) 3.07
Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol (1998) 3.05
Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev (1999) 2.91
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (1998) 2.83
Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77
A target for Src in mitosis. Nature (1994) 2.65
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem (2000) 2.46
The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol (2007) 2.39
Identification of Src, Fyn, and Lyn SH3-binding proteins: implications for a function of SH3 domains. Mol Cell Biol (1994) 2.37
Molecular cloning and nucleic acid binding properties of the GAP-associated tyrosine phosphoprotein p62. Cell (1992) 2.32
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell (2001) 2.26
Arginine methylation inhibits the binding of proline-rich ligands to Src homology 3, but not WW, domains. J Biol Chem (2000) 2.20
STAR, a gene family involved in signal transduction and activation of RNA. Trends Genet (1997) 2.14
Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol (1993) 2.14
Self-association of the single-KH-domain family members Sam68, GRP33, GLD-1, and Qk1: role of the KH domain. Mol Cell Biol (1997) 2.11
Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A (2001) 2.08
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A (2009) 2.01
c-Met is essential for wound healing in the skin. J Cell Biol (2007) 1.98
Specificity and determinants of Sam68 RNA binding. Implications for the biological function of K homology domains. J Biol Chem (1997) 1.96
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol (1995) 1.94
Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat (1989) 1.92
Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest (2000) 1.90
Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol (2004) 1.88
Sam68 RNA binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. Mol Biol Cell (2003) 1.87
Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol (1996) 1.86
The role of SF/HGF and c-Met in the development of skeletal muscle. Development (1999) 1.85
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res (2008) 1.82
A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell (2002) 1.82
Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells. J Pathol (2010) 1.82
Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res (2002) 1.78
A role for the GSG domain in localizing Sam68 to novel nuclear structures in cancer cell lines. Mol Biol Cell (1999) 1.76
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res (2007) 1.75
Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene (1994) 1.75
Cross-talk between the proto-oncogenes Met and Ron. Oncogene (2000) 1.71
Crosstalk in Met receptor oncogenesis. Trends Cell Biol (2009) 1.70
Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci U S A (1994) 1.67
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res (2011) 1.67
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene (1995) 1.66
Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol (2005) 1.65
The quaking I-5 protein (QKI-5) has a novel nuclear localization signal and shuttles between the nucleus and the cytoplasm. J Biol Chem (1999) 1.59
P62 association with RNA is regulated by tyrosine phosphorylation. J Biol Chem (1995) 1.59
BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res (1999) 1.59
Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem (1999) 1.58
Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. Mol Cell Biol (2000) 1.58
Association of p62, a multifunctional SH2- and SH3-domain-binding protein, with src family tyrosine kinases, Grb2, and phospholipase C gamma-1. Mol Cell Biol (1995) 1.58
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol (1996) 1.58
Partial characterization of a hepatocyte growth factor from rat platelets. J Cell Physiol (1984) 1.56
Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem (1996) 1.56
Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol (2010) 1.55
HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. Development (1995) 1.54
Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int J Cancer (1997) 1.53
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res (2009) 1.52
Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer (1997) 1.50
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene (2003) 1.49
Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene (2000) 1.48
Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem (2005) 1.47
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res (2007) 1.47
The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene (2007) 1.47
Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res (2003) 1.45
Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene (2004) 1.43
Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol (1999) 1.43
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A (2009) 1.42
Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res (1995) 1.40
Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene (2006) 1.40
Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer (1994) 1.36
Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci U S A (2008) 1.36
The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. J Biol Chem (2004) 1.36
Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer (1996) 1.35
Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J Biol Chem (2002) 1.31
Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci (1994) 1.29
Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res (2007) 1.27
HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell (2004) 1.26
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther (2006) 1.26
Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res (2008) 1.26
Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem (2004) 1.25
Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res (2008) 6.46
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res (2007) 1.75
Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol (2006) 1.64
Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol (2004) 1.40
Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol (2008) 1.40
Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol (2007) 1.36
Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol (2003) 1.31
Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem (2004) 1.25
Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol (2004) 1.24
Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res (2010) 1.14
MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol (2003) 1.11
MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med (2013) 1.08
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res (2012) 1.08
Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle (2013) 1.07
Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids (2005) 1.04
Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications. Steroids (2010) 1.03
Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol (2010) 1.02
Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res (2013) 1.02
The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol (2010) 1.01
ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol (2011) 1.00
Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol Cell Endocrinol (2009) 0.98
Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci U S A (2009) 0.97
Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer (2009) 0.94
PELP1: a review of PELP1 interactions, signaling, and biology. Mol Cell Endocrinol (2013) 0.92
Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab (2011) 0.92
Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK. Breast Cancer Res (2011) 0.90
Role of phosphorylation in progesterone receptor signaling and specificity. Mol Cell Endocrinol (2011) 0.88
Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation. Steroids (2008) 0.87
Steadying the boat: integrating mechanisms of membrane and nuclear-steroid-receptor signalling. EMBO Rep (2005) 0.86
Progesterone promotes focal adhesion formation and migration in breast cancer cells through induction of protease-activated receptor-1. J Endocrinol (2012) 0.86
Met receptors induce Sam68-dependent cell migration by activation of alternate extracellular signal-regulated kinase family members. J Biol Chem (2011) 0.86
A novel interaction [corrected] of nucleolin with Rad51. Biochem Biophys Res Commun (2006) 0.85
A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res (2013) 0.85
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Mol Endocrinol (2014) 0.84
Scaffolding actions of membrane-associated progesterone receptors. Steroids (2008) 0.83
Delta(9)-Tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture. Neuropharmacology (2005) 0.83
Cross-talk between growth factor and progesterone receptor signaling pathways: implications for breast cancer cell growth. Breast Dis (2003) 0.81
Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events. Horm Cancer (2010) 0.80
Dynamic regulation of steroid hormone receptor transcriptional activity by reversible SUMOylation. Vitam Horm (2013) 0.77
2-Methoxyestradiol inhibits progesterone-dependent tissue factor expression and activity in breast cancer cells. Horm Cancer (2010) 0.76
Editorial: membrane and nuclear steroid hormone receptors: two integrated arms of the same signaling pathway? Steroids (2007) 0.76
Lost in translation: can we afford to miss the trees for the forest? Horm Cancer (2014) 0.75
Statement of principle. Horm Cancer (2015) 0.75
Statement of principle. Endocr Rev (2014) 0.75
Meeting review: Extra-nuclear steroid receptors-Integration with multiple signaling pathways. Steroids (2008) 0.75
Statement of principle. J Clin Endocrinol Metab (2014) 0.75
Breast cancer and pregnancy. Obstet Gynecol Clin North Am (2005) 0.75
Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor. Endocrine (2014) 0.75